Seeking Alpha
 

ArthroCare Corporation (ARTC)

- NASDAQ
ARTC is defunct.
  • May 2, 2014, 4:40 PM
    • Total revenues: $96.1M (+4.1%): product sales: $90M (+2.9%),  royalties/other: $6.1M (+24.5%).
    • Product sales: Sports Medicine: $63.8M (+7.0%), ENT: $24.3M (-5.1%), Other: $1.8M (-18.2%).
    • Operating income: $9.2M (-31.9%).
    • Net Income: $6.2M (-44.6%), EPS: $0.10 (-66.7%).
    • Cash and equivalents at quarter end: $191M.
    • CF Ops: -$20.6M compared to +$19.5M yoy.
    • (ARTC)
    | Comment!
  • May 2, 2014, 4:25 PM
    • ArthroCare (ARTC): Q1 EPS of $0.32 misses by $0.04.
    • Revenue of $96.06M (+4.0% Y/Y) beats by $0.26M.
    • Shares -0.01% AH.
    • Press Release
    •  
    | Comment!
  • Mar. 6, 2014, 3:49 PM
    • JMP Securities downgrades ArthoCare (ARTC) to Market Perform representing the fifth sell-side downgrade since January.
    • William Blair, Craig-Hallum, BMO Capital and Northcoast Research all rate the company Neutral or Market Perform.
    • Shares are off a fraction on 50% higher volume in today's trading.
    | Comment!
  • Mar. 6, 2014, 9:54 AM
    • William Blair downgrades ArthoCare (ARTC) to Market Perform from Outperform.
    • The stock gapped up on January 8 after the US Department of Justice issued a Deferred Prosecution Agreement resolving its securities fraud investigation by the previous management team.
    • Shares are up 22% in 2014.
    | Comment!
  • Feb. 13, 2014, 4:08 PM
    • ArthroCare Corporation (ARTC): Q4 EPS of $0.30 misses by $0.09.
    • Revenue of $101.7M (+4.9% Y/Y) beats by $1.05M.
    • Press Release
    | Comment!
  • Feb. 3, 2014, 9:09 AM
    | 8 Comments
  • Feb. 3, 2014, 2:25 AM
    • Smith & Nephew (SNN) has agreed to acquire ArthroCare (ARTC) for $1.7B in a move that Smith & Nephew says will strengthen its global sports medicine business.
    • Smith & Nephew is offering $48.25 a share, 6.3% above ArthroCare's closing price of $45.38 on Friday. (PR)
    | Comment!
  • Jan. 8, 2014, 2:09 PM
    • "We believe the stock will trade less on fundamentals and more on the take-out potential, [so] we once again put pen to paper to provide clarity on what we feel the different buyers are willing/able to pay," Canaccord says, regarding the outlook for ArthroCare (ARTC +18.8%) in the wake of the DPA announced Tuesday.
    • Analyst William Plovanic says the shares could be valued at "above $55 for an acquirer that planned on keeping most infrastructure."
    • For potential suitors with "existing infrastructure in sports med and ENT," Plovanic sees $80+.
    | Comment!
  • Jan. 8, 2014, 12:46 PM
    | 2 Comments
  • Jan. 7, 2014, 6:16 PM
    • ArthroCare (ARTC) +10.9% AH enters into a deferred prosecution agreement with the Justice Department which resolves the DOJ investigation regarding allegations of securities and related fraud committed under a previous management team.
    • As part of the agreement, ARTC will pay a $30M fine to the DOJ and maintain a compliance program that it must report on annually.
    | Comment!
  • Oct. 29, 2013, 5:02 PM
    • ArthroCare (ARTC): Q3 EPS of $0.27.
    • Revenue of $91.9M (+5.7% Y/Y) beats by $2.77M. (PR)
    | Comment!
  • Aug. 5, 2013, 4:17 PM
    • ArthroCare (ARTC): Q2 EPS of -$0.27.
    • Revenue of $92.1M misses by $1.57M. Shares +6.1% AH. (PR)
    | Comment!
  • Jul. 2, 2013, 9:29 AM
    ArthroCare (ARTC) acquires privately held ENTrigue Surgical for $45M in cash. (PR)
    | Comment!
  • May 7, 2013, 5:13 PM
    ArthroCare (ARTC): Q1 EPS of $0.30 misses by $0.07. Revenue of $92.3M misses by $2.11M. (PR)
    | Comment!
  • Feb. 13, 2013, 4:53 PM
    ArthroCare (ARTC): Q4 EPS of $0.3 misses by $0.07. Revenue of $96.9M (+4.9% Y/Y) beats by $3.12M. (PR)
    | Comment!
  • Oct. 31, 2012, 4:06 PM
    ArthroCare (ARTC): Q3 EPS of $0.27 misses by $0.01. Revenue of $86.9M (+4.4% Y/Y) beats by $2.3M. Shares -0.5% AH. (PR)
    | Comment!
Visit Seeking Alpha's
Company Description
ArthroCare Corporation develops, manufactures and markets minimally invasive surgical products, many of which are based on its patented Coblation(r) technology. The Company's business consists of two core product areas: Sports Medicine and ENT.